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Abstract
Background: Management decisions are not straightforward when the Ultrasound Guided Fine Needle Aspiration
(USFNA) demonstrates a Bethesda score of either category III or IV, and a diagnostic hemi-thyroidectomy or a
repeat USFNA (r-USFNA) could be performed. The aim of this study is to assess the effectiveness of r-USFNA in the
management of indeterminate thyroid nodules by evaluating the likelihood of obtaining a definite diagnosis.
Methods: We reviewed the medical records of all patients with thyroid nodules between 2011 and 2015 at the
Jewish General Hospital (Montreal, Canada). Three hundred fifty-one patients who had undergone a surgical
procedure (hemi or total thyroidectomy) and a diagnosis of B3 or B4 on the primary USFNA (p-USFNA) were
included in the study. Ninety-six of the included patients also had a repeat USFNA prior to the surgery.
Demographic data, type of procedure, and McGill Thyroid Nodule Score (MTNS) were obtained from the medical
records. Malignancy rates were calculated based on the final surgical histopathology report.
Results: Upon r-USFNA, an average 76 % of patients did not change Bethesda categories, 7.4 % downgraded to a
benign category. The results showed that, on an average 17.3 % of patients with p-USFNA of B3 and 20 % of
patients with p-USFNA of B4, upgraded to a malignant or suspicious for malignancy category, thus changing the
clinical management to total thyroidectomy. Our data demonstrates that r-USFNA facilitates choosing the correct
surgery of total thyroidectomy in about 20 % of nodules that have upgraded from B3/B4 to a more definite
malignant category.
Conclusions: r-USFNA in patients with indeterminate diagnoses (B3 or B4) increases categorization into more
definite categories. Approximately 20 % of patients are found to have malignant thyroid nodules and suspicious
for malignancy thyroid nodules upon repeating the biopsy, hence a diagnostic hemi-thyroidectomy was avoided
and a more definitive surgery could be performed. Furthermore, repeat USFNA results in a fewer number of
hemi-thyroidectomy and completion thyroidectomy procedures.
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Background
Ultrasound Guided Fine Needle Aspiration (USFNA) is
a cost-effective and highly reliable procedure used to
evaluate and guide the management of thyroid nodules
[1]. The Bethesda System for Reporting Thyroid Cytopa-
thology (BSRTC) has resulted in standardization, repro-
ducibility and improved clinical significance of thyroid
USFNA. It is comprised of the following six categories:
B1, non-diagnostic; B2, benign; B3, Atypia of undeter-
mined significance or follicular lesion of undetermined
significance; B4, (suspicious for) Follicular neoplasm; B5,
Suspicious for malignancy; B6, malignant. Management
decisions are not straightforward when the USFNA dem-
onstrates a Bethesda score of either category III (B3) or IV
(B4) [2–6]. In those instances, it is not uncommon for
some patients to undergo diagnostic hemi-thyroidectomy
to obtain a definitive diagnosis, while others prefer a more
conservative approach and opt for a repeat USFNA
(r-USFNA). However, none of these scenarios are ideal. A
hemi-thyroidectomy is rarely the procedure of choice for
a thyroid nodule: it is either unnecessary (in the event of a
benign lesion) or inadequate (in the event of a malignant
lesion). Likewise, the benefit of repeat USFNA is unclear
with respect to its contribution to patient management. If
the r-USFNA results in Bethesda II (B2), Bethesda V (B5)
or Bethesda VI (B6), then management recommendations
are more clear and the test is deemed to be useful. How-
ever, if the test yields a Bethesda I (B1), B3, or B4, then r-
USFNA is not helpful. The aim of this study is to assess
the effectiveness of repeat USFNA in the management of
indeterminate thyroid nodules (B3 and B4) by evaluating
the likelihood of obtaining a definite diagnosis. Moreover,
this investigation assesses the usefulness of r-USFNA in
the prevention of completion hemi-thyroidectomies in pa-
tients with initial B3 or B4 diagnoses.
Methods
A retrospective chart review of all patients with thyroid
nodules classified by BSRTC who underwent a hemi- or
total thyroidectomy between 2011 and 2015 at the Jewish
General Hospital (Montreal, Canada) was performed.
Three hundred fifty-one patients who had undergone a
surgical procedure (hemi or total thyroidectomy) and a
diagnosis of B3 or B4 on the primary USFNA (p-USFNA)
were included in the study. Ninety-six of the included pa-
tients also had a repeat USFNA prior to the surgery.
Demographic data, type of procedure, and McGill Thyroid
Nodule Score (MTNS) were obtained from the medical
records. Patients with missing medical data or a diagnosis
other than B3 or B4 on p-USFNA were excluded
from the study. Malignancy rates were calculated
based on the final surgical histopathology report. Fine
needle aspirations were performed by otolaryngolo-
gists or interventional radiologists under ultrasound
guidance using 25- or 27-gauge needle with typically
one to four passes.
The decision to undergo thyroidectomy in the patient
population was influenced by a high McGill Thyroid
Nodule Score (MTNS). MTNS was previously shown to
accurately represent the risk of malignancy in a thyroid
nodule, given it takes into account a variety of demo-
graphic and clinical risk factors in addition to the cyto-
logical features evident on USFNA [7]. Other significant
operative criteria for our patients included worrisome
features on ultrasound, clinical suspicion and patient
preference [8]. In addition, diagnostic surgery was rec-
ommended to patients with two consecutive diagnoses
of B3 or B4 on p-USFNA and r-USFNA.
All statistical analyses were performed using SPSS
(IBM Corp., Armonk, NY). This study was approved by
the institutional Ethics Review Board (protocol CR15-20).
Results
A total of 96 patients were retained in this study (Table 1).
The mean age at diagnosis was 50.7 years (82.3 % female).
Table 1 summarizes the pathological characteristics of the
excised nodules. The lesions were categorized according
to the final histopathological report as benign (40.6 %) or
Table 1 Patient demographics and pathological characteristics









Nature of lesions, n (%)
Benign 39 (40.6)
Malignant 57 (59.4)
Type of Lesion, n (%)
Papillary Carcinoma 56 (58.3)
Follicular Adenoma 25 (26.0)
Other 15 (15.6)
Histology, n (%)
Unifocal lesion 63 (65.6)
Multifocal lesion 33 (34.4)
Size of Malignant Lesion, n (%)
size < 1 cm 17 (29.8)
1 = < size < 2 cm 21 (36.8)
2 = < size < 4 cm 17 (29.8)
size > = 4 cm 2 (3.5)
Jooya et al. Journal of Otolaryngology - Head and Neck Surgery  (2016) 45:51 Page 2 of 6
malignant (59.4 %). Papillary thyroid carcinoma comprised
the most common type of histology (58.3 % of all lesions).
56.6 % of nodules were multifocal in histology. In addition,
the highest proportion (36.8 %) of malignant thyroid nod-
ules in this study were between 1 and 1.9 cm.
Nodules were reclassified after r-USFNA as suspicious
for malignancy or malignant (B5 or B6) in 17.3 % of B3
and 20.0 % of B4 nodules. Moreover, 7.4 % of patients
with a score of B3 on p-USFNA had a result of benign
lesion (B2) on r-USFNA. The proportion of malignancy
on final histopathological reports of lesions categorized
as B3 or B4 on primary and repeat USFNAs is shown in
Table 2. After p-USFNA, 58.0 % of nodules categorized as
B3 and 66.7 % of B4 lesions were found to be malignant.
Similarly, 54.6 % of lesions classified as B3 after r-USFNA
and 55.7 % of B4 were confirmed to be malignant.
The distribution of Bethesda categories after r-USFNA
for lesions initially diagnosed as either B3 or B4 is demon-
strated in Table 3, and the corresponding percentage of
malignancy of each category is summarized in Table 4.
In addition, differences in the rates of hemi- and comple-
tion thyroidectomies between patients with and without a
repeat USFNA has been investigated (Table 5). 255 patients
had only one USFNA study and did not undergo a repeat
procedure; 121 of these patients had a hemi-thyroidectomy
operation (47.45 %). Out of the 96 patients who had a re-
peat USFNA after the diagnosis of B3 or B4 on p-USFNA,
36 underwent hemi-thyroidectomy (37.50 %). Furthermore,
16 out of 255 patients (6.27 %) without r-USFNA under-
went completion thyroidectomy, compared to 3 out of 96
(3.12 %) in patients who obtained a r-USFNA.
Discussion
Although previous studies have compared the outcomes
of repeat USFNAs with the primary ones, post-operative
histopathological data has been missing from all the pre-
vious similar studies, except one by VanderLaan [1]. This
study is the first to examine the significance of repeating
USFNA in patients with p-USFNA diagnosis of B4, and
to explore the significance of r-USFNA in guiding the
clinical decision of performing hemi-thyroidectomy ver-
sus total thyroidectomy for indeterminate nodules. This
study aims to address the gap in the literature with
regards to correlation of results of repeat USFNA and
final surgical pathology. However, there exists a trade off
between having definite histopathological data and
selecting a well-representative sample from the patient
population. Necessitating previous hemi- or total thy-
roidectomy, as an inclusion criterion in this study, may
act to introduce a source of selection bias.
Bethesda categories B3 and B4 comprise a variety of het-
erogeneous lesions that are neither benign (category B2)
nor sufficiently atypical for making a diagnosis of suspi-
cious (category B5) or malignant (category B6) lesions
[9–11]. Thus, there is great variability in the literature
as to whether patients with such indeterminate diag-
noses should undergo surgery or not. Previous inves-
tigations have demonstrated that r-USFNA increases
the rate of reclassification of indeterminate nodules
into one of the more definitive categories of BSRTC
and a higher percentage diagnosis of malignancy (cat-
egories B5 or B6) [1, 2, 5, 6, 12–15]. However, there
exists great variation surrounding the extent of such re-
classification in the literature. The percentage of B3 le-
sions on p-USFNA that upgrade into a more definitive
category of B5 or B6 upon performing r-USFNA ranges
from 1.35 to 24.77 % with an average of 11.03 % of cases
Table 2 Proportion of malignancy as a function of Bethesda
score for p-USFNA and r-USFNA




p-USFNA B3 81 (84.4) 47 (58.0)
B4 15 (15.6) 10 (66.7)
r-USFNA B3 55 (73.3) 30 (54.6)
B4 18 (26.7) 10 (55.7)
Abbreviations: p-USFNA primary fine-needle aspiration, r-USFNA Repeat fine-needle
aspiration, B3 Bethesda score III, B4 Bethesda score IV
Table 3 Distribution of repeat USFNA cytology according to
initial Bethesda classification
p-USFNA r-USFNA
B2 B3 B4 B5 B6 Total
B3
Frequency 6 50 11 14 0 81
% 7.4 77.2 13.6 17.3 0
B4
Frequency 0 5 7 1 2 15
% 0 33.3 46.7 6.7 13.3
Total 96
Abbreviations: p-USFNA primary fine-needle aspiration, r-USFNA Repeat fine-needle
aspiration, B2 Bethesda score II, B3 Bethesda score III, B4 Bethesda score IV, B5
Bethesda score V, B6 Bethesda score VI
Table 4 Percent malignancy of individual Bethesda scores after
repeat USFNA, as compared with initial USFNA
p-USFNA r-USFNA Number of cases (%) Malignant final
pathology, n (%)
B3 B2 6 (7.4) 0 (0.0)
(n = 81) B3/B4 61 (75.3) 33 (54.01)
B5/B6 14 (17.3) 14 (100.0)
B4 B2 0 (0) 0 (NA)
(n = 15) B3/B4 12 (80) 7 (58.33)
B5/B6 3 (20) 3 (100.0)
Abbreviations: p-USFNA primary fine-needle aspiration, r-USFNA Repeat fine-needle
aspiration, B2 Bethesda score II, B3 Bethesda score III, B4 Bethesda score IV, B5
Bethesda score V, B6 Bethesda score VI
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[6, 12, 15–21]. Our data shows that performing a second
USFNA results in an upgrade from indeterminate to more
definitive categories of Bethesda classification in approxi-
mately 20 % of patients, hence changing their clinical
management. Specifically, as a result of r-USFNA, surgical
intervention was chosen over clinical follow up in 17.3
and 20.0 % of patients with initial BSRTC score of B3 and
B4 respectively.
The efficacy of r-USFNA in avoiding a completion thy-
roidectomy has also been assessed in this study. Diagnos-
tic hemi-thyroidectomy for B3 nodules is not uncommon,
and similarly, BSRTC recommends performing lobectomy
for B4 lesions. However, our data demonstrates that r-
USFNA facilitates choosing the correct surgery (i.e. total
thyroidectomy) in about 20 % of nodules that were
upgraded from B3/B4 to a more definite malignant cat-
egory. In these patients, diagnostic hemi- and therapeutic
completion thyroidectomies could be avoided. The same
concept applies for patients downgraded to a benign diag-
nosis. In this investigation, 7.4 % of nodules downgraded
from B3 to a benign category of B2 after repeating the
USFNA. In this group of patients, the clinical manage-
ment would have changed to a more conservative one not
warranting surgery, had they not had a high MTNS score.
The proportion of cases in our study that downgraded to
a benign score of B2 after r-USFNA are not consistent
with those reported in the literature however, ranging
from 42.3 to 78.4 % of cases (average 60.3 %) [6, 16–18,
20, 21]. The reason for this discrepancy could be attrib-
uted to the very small number of samples in our study
that had a repeat USFNA score of B2. In this study, re-
peating USFNA has been proven to be effective in identi-
fying nodules that are malignant and suspicious for
malignancy to undergo total thyroidectomy, but not in
ruling-out surgery for benign nodules upon r-USFNA.
The reason behind such difference could be due to the
fact that all patients in this study had met operative cri-
teria, based on their MTNS score.
In brief, although as per latest guidelines published by
the American Thyroid Association, hemi-thyroidectomy
may be beneficial in definitive histological diagnosis of
indeterminate nodules, repeat USFNA could lead to a
clarity of diagnosis preventing the need for lobectomy
[22]. In specific, repeat USFNA of an indeterminate nod-
ule may lead to a change to a more conservative man-
agement of a benign nodule or upstaging and total
thyroidectomy for a malignant lesion. These results have
potential implications for cost reduction in the health
care system, prevention of patient work absenteeism,
and the avoidance of repeat anesthesia.
The analysis of our thyroidectomy database revealed
that performing a second USFNA biopsy decreased the
number of hemi-thyroidectomy procedures by 9.95 %
and prevented a second surgery in approximately 3 % of
cases. The discrepancy between the predicted (20 %) and
actual (3 %) rate of reduction in completion thyroidec-
tomy surgeries could be attributed to the fact that many
of our patients with one USFNA result of B3/B4 under-
went total thyroidectomy in the context of a high MTNS
score and increased clinical suspicion of malignancy.
Although no data in the literature compared changes
in BSRTC categories after repeating USFNA in nodules
initially classified as B4, our results for B3 cases on p-
USFNA are consistent with the values reported in simi-
lar investigations. Specifically, our results show that the
proportion of nodules that were reclassified from B3 into
B5/B6 after r-USFNA are similar to those reported by
VanderLaan (17.8 %), Chen (15.4 %), Yassa (14.16 %) and
Baloch (19.42 %) [16, 17, 21, 23].
Our results demonstrate a greater rate of malignancy
than what is reported in the BSRTC classification. Ac-
cording to the BSRTC, the risk of malignancy is reported
to be 5–15 % for a diagnosis of B3, and 15–30 % for B4
[9]. However, a systematic review has demonstrated a
large variation in the risk of malignancy associated with
B3 classification, ranging from 6 to 96.7 % (average of
32.7 %) [3, 14, 15, 23]. Likewise, similar issues occur for
the B4 classification. In our study, the overall risk of ma-
lignancy, as confirmed by the histopathological data, for
a thyroid nodule classified as B3 or B4 on p-USFNA was
higher than previous reports in the literature, with
58.0 % of B3 and 66.7 % of B4 nodules confirmed to be
malignant [1–5, 11]. This difference could be explained
by the fact that all the patients included in our study
had undergone either hemi- or full thyroidectomy pro-
cedure, potentially leading to a selection bias. Further-
more, the heterogeneous nature of B3 and B4 categories
and disparities in their interpretations could be consid-
ered another factor that has led to the higher rates of
malignancies in this study.
The decision to perform surgery in our patient popula-
tion was not solely limited to the results of the USFNA,
but was also influenced by a high MTNS score. MTNS
portrays a more accurate account of risk of malignancy
by taking into consideration salient factors such as
Table 5 Frequency and percentage of hemi- and completion
thyroidectomy operations in patients with one or two USFNA












121 (47.45) 16 (6.27) 255
p-USFNA
(B3 or B4) +
r-USFNA
36 (37.50) 3 (3.12) 96
Abbreviations: p-USFNA primary fine-needle aspiration, r-USFNA Repeat fine-needle
aspiration, B3 Bethesda score III, B4 Bethesda score IV
Jooya et al. Journal of Otolaryngology - Head and Neck Surgery  (2016) 45:51 Page 4 of 6
patient demographics, family history and previous radi-
ation exposure. It also incorporates adverse features on
ultrasound and on PET scans as an adjunct to the cyto-
logical properties of nodules. Thus, an elevated clinical
suspicion of malignancy as suggested by the MTNS
score, in conjunction with patient and physician prefer-
ences, comprise the operative criteria in our institution
and guide the clinical decision making.
There are a number of limitations to this study. First,
since all of the patients in this investigation have under-
gone surgery, a selection bias may explain the higher
calculated risk of malignancy of B3/B4 nodules. Other
limitations include the retrospective nature of the study
and the small number of samples that have a repeat
USFNA result consistent with a benign nodule (B2).
Conclusions
Repeating USFNA in patients with indeterminate diag-
noses (B3 or B4) increases categorization into more def-
inite diagnostic categories. Close to 20 % of patients are
found to have malignant or suspicious thyroid nodules
upon repeating the biopsy, hence a diagnostic hemi-
thyroidectomy was avoided and a more definitive sur-
gery could be performed. Furthermore, repeat USFNA
results in a fewer number of hemi-thyroidectomy and
completion thyroidectomy procedures.
Abbreviations
B2: Bethesda score II; B3: Bethesda score III; B4: Bethesda score IV;
B5: Bethesda score V; B6: Bethesda score VI; BSRTC: Bethesda System for
Reporting Thyroid Cytopathology; p-USFNA: Primary Fine Needle Aspiration;
r-USFNA: Repeat Fine Needle Aspiration; USFNA: Ultrasound Guided Fine
Needle Aspiration
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